Scarica l'app Stockscreener
9.90
2.06%
0.20
Pre-mercato:
9.89
-0.010
-0.10%
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
| Data di fine periodo | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
| Revenues |
19.00%
71.54
|
60.12 | 60.10 | 54.27 | 48.06 |
Operating Expenses
|
6.09%
67.06
|
63.21 | 58.42 | 67.16 | 56.25 |
| Benefits Costs and Expenses |
-
|
- | 260.17 | - | - |
| Costs And Expenses |
6.09%
67.06
|
63.21 | 81.88 | 67.16 | 56.25 |
| Operating Income/Loss |
245.05%
4.482
|
-3.09 | 1.679 | -12.89 | -8.187 |
| Income/Loss From Continuing Operations Before Tax |
875.91%
71.54
|
-9.22 | -200.07 | 54.27 | -15.01 |
| Income Tax Expense/Benefit, Deferred |
-
|
- | - | -3.324 | 0.749 |
| Income Tax Expense/Benefit |
-
|
- | - | -3.324 | 0.749 |
| Income/Loss From Continuing Operations After Tax |
79.09%
-1.928
|
-9.22 | -5.113 | -15.74 | -15.01 |
|
Net Income/Loss
|
79.09%
-1.928
|
-9.22 | -5.113 | -15.74 | -15.01 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
4.60%
159.46
|
152.45 | 0.8106 | 148.99 | 148.35 |
| Diluted Average Shares |
4.60%
159.46
|
152.45 | 0.8106 | 148.99 | 148.35 |
| Basic Earnings Per Share |
83.33%
-0.01
|
-0.06 | -0.03 | -0.11 | -0.10 |
| Diluted Earnings Per Share |
83.33%
-0.01
|
-0.06 | -0.03 | -0.11 | -0.10 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
0.64%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):